Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2-MBC in the real world

被引:3
|
作者
Kruse, Megan [1 ]
Smyth, Emily Nash [2 ]
Bowman, Lee [2 ]
Gautam, Santosh [3 ]
Guimaraes, Claudia M. [2 ]
Nisbett, Alnecia R. [3 ]
Fisher, Maxine D. [3 ]
Cui, Zhanglin Lin [2 ]
Sheffield, Kristin M. [2 ]
Kalinsky, Kevin [4 ]
机构
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA
[2] Eli Lilly & Co, Indianapolis, IN USA
[3] ConcertAI, Memphis, TN USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30307 USA
关键词
Abemaciclib; CDK4 & 6i; Metastatic breast cancer; Real-world evidence; Sequential treatment; BREAST-CANCER; COMBINATION; ABEMACICLIB; RIBOCICLIB; LETROZOLE; SURVIVAL; THERAPY;
D O I
10.1007/s10549-023-06993-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeCyclin Dependent Kinase 4 & 6 inhibitors (CDK4 & 6i) have transformed the management of HR+, HER2- metastatic breast cancer (MBC); however, the optimal sequence of these treatments and other systemic therapies for MBC remains unclear.MethodsThis study analyzed electronic medical records from the ConcertAI Oncology Dataset. US patients who received abemaciclib and at least one other systemic line of therapy (LOT) for HR+, HER2- MBC were eligible. Treatment sequences were grouped, and data for two pairs of groups are presented herein (N = 397): Group 1 (1L CDK4 & 6i to 2L CDK4 & 6i) vs. Group 2 (1L CDK4 & 6i to 2L non-CDK4 & 6i), and Group 3 (2L CDK4 & 6i to 3L CDK4 & 6i) vs. Group 4 (2L CDK4 & 6i to 3L non-CDK4 & 6i). Time-to-event outcomes (PFS and PFS-2) were analyzed using Kaplan-Meier method and Cox proportional hazard regression.ResultsIn the total cohort of 690 patients, the most prevalent sequence was 1L CDK4 & 6i to 2L CDK4 & 6i (n = 165). For the 397 patients across Groups 1-4, sequential CDK4 & 6i demonstrated numerically longer PFS and PFS-2 versus non-sequential CDK4 & 6i. Adjusted results demonstrate that patients in Group 1 demonstrated significantly longer PFS (p = 0.05) versus Group 2.ConclusionsAlthough retrospective and hypothesis-generating, these data demonstrate numerically longer outcomes in the subsequent LOT associated with sequential CDK4 & 6i treatment.
引用
收藏
页码:105 / 115
页数:11
相关论文
共 50 条
  • [1] Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world
    Megan Kruse
    Emily Nash Smyth
    Lee Bowman
    Santosh Gautam
    Claudia M. Guimaraes
    Alnecia R. Nisbett
    Maxine D. Fisher
    Zhanglin Lin Cui
    Kristin M. Sheffield
    Kevin Kalinsky
    Breast Cancer Research and Treatment, 2023, 201 : 105 - 115
  • [2] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
  • [3] Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil
    Queiroz, Marcello Moro
    Sacardo, Karina Perez
    Ribeiro, Mauricio Fernando
    Gadotti, Luiza Lara
    Saddi, Rodrigo
    Oliveira, Leandro Jonata de Carvalho
    Linck, Rudinei Diogo Marques
    Cruz, Marcelo Rocha de Souza
    Barroso-Sousa, Romualdo
    Sahade, Marina
    Correa, Tatiana Strava
    Mano, Max Senna
    Suzuki, Daniele Assad
    Shimada, Andrea Kazumi
    Katz, Artur
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 35
  • [4] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer at a Single Cancer Center
    Knudsen, Erik S.
    Schultz, Emily
    Hamilton, Deanna
    Attwood, Kris
    Edge, Stephen
    O'Connor, Tracey
    Levine, Ellis
    Witkiewicz, Agnieszka K.
    ONCOLOGIST, 2022, 27 (08) : 646 - 654
  • [5] CDK4/6 inhibitors in advanced HR+/HER2-breast cancer - a multicenter real world data analysis
    Mueller, C.
    Kiver, V
    Solomayer, E-F
    Wagenpfeil, G.
    Neeb, C.
    Blohmer, J. U.
    Abramian, A., V
    Maass, N.
    Schuetz, F.
    Kolberg-Liedtke, C.
    Ralser, D. J.
    Rambow, A-C
    BREAST CARE, 2023, 18 (01) : 31 - 41
  • [6] Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2-Advanced Breast Cancer
    Patel, Ram
    Mathews, John
    Hamm, Caroline
    Kulkarni, Swati
    Gupta, Rasna
    Opperman, Tarquin
    Chiong, John Dean
    Nasser, Abdullah
    CURRENT ONCOLOGY, 2025, 32 (01)
  • [7] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
  • [8] Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2-Metastatic Breast Cancer
    Zhao, Joseph J.
    Fong, Khi Yung
    Chan, Yiong Huak
    Tey, Jeremy
    Dawood, Shaheenah
    Lee, Soo Chin
    Finn, Richard S.
    Sundar, Raghav
    Lim, Joline S. J.
    CANCERS, 2023, 15 (18)
  • [9] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
  • [10] Real-world effectiveness of CDK4/6 inhibitors on patients with HR+/HER2-advanced breast cancer in South Korea, focusing on underrepresented patients
    Jung, Hye-In
    Kwon, Sun-Hong
    Nam, Jin Hyun
    Cho, Jeong-Yeon
    Lee, Eui-Kyung
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (06) : 967 - 975